Richard Nolan Townsend Sells 3,345 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 3,345 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $4.95, for a total transaction of $16,557.75. Following the completion of the sale, the chief executive officer directly owned 374,472 shares of the company’s stock, valued at $1,853,636.40. The trade was a 0.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Wednesday, July 1st, Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $4.48, for a total value of $116,242.56.

Lexeo Therapeutics Stock Performance

Shares of LXEO opened at $5.06 on Friday. The stock has a 50 day simple moving average of $4.72 and a 200 day simple moving average of $5.55. Lexeo Therapeutics, Inc. has a 52-week low of $3.99 and a 52-week high of $10.99. The firm has a market capitalization of $415.15 million, a PE ratio of -4.40 and a beta of 1.46.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Equities research analysts predict that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current fiscal year.

Analysts Set New Price Targets

LXEO has been the subject of a number of recent research reports. Chardan Capital upgraded shares of Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. lowered their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, June 25th. Wall Street Zen lowered Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $18.75.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new stake in Lexeo Therapeutics during the second quarter worth $32,000. Allworth Financial LP grew its position in shares of Lexeo Therapeutics by 1,002.9% in the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after acquiring an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after acquiring an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Lexeo Therapeutics during the 4th quarter worth about $37,000. Finally, California State Teachers Retirement System increased its stake in shares of Lexeo Therapeutics by 123.7% during the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.